Tirzepatide comes in doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg
This creates potential for inappropriate use or suboptimal patient outcomes
In addition to glycemic control and weight loss, certain GLP-1 receptor agonists have FDA-approved indications to lower the risk for major adverse cardiovascular events, address moderate to severe obstructive sleep apnea, and, most recently, reduce the risk for worsening kidney disease, kidney failure, and cardiovascular death
Proper semaglutide vial storage is essential because it keeps the medication effective and safe to use
Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al